LA VACUNA CONTRA EL NEUMOCOCO 13 ES RECOMENDADA PARA LOS ADULTOS CON ALTO RIESGO Y ADULTOS MAYORES EN RIESGO, ES INTERESANTE LA EVOLUCIÓN DE ESTA IMPORTANTE VBACUNA QUE DISMINUYE LA ENFERMEDAD EN LOS PROTEGIDOS Y SU ENTORNO CUANDO SE USA EN ALTAS COBERTURAS.
ABAJO LOS DETALLES,
Compartiendo con amigos en el pasado Congreso Nacional de Pediatría Septiembre 2012
SALUD,
This message serves to inform you about the new ACIP recommendations to
give PCV13 (Prevnar 13) to high-risk adults and includes reviews on existing
PPSV23 (Pneumovax) recommendations for adults.
Now on Medscape, CDC expert Tamara Pilishvili, MPH, talks about the new
Advisory Committee on Immunization Practices (ACIP) recommendations to give
PCV13 (Prevnar 13) to high-risk adults and reviews existing PPSV23 (Pneumovax)
recommendations for adults. This
overview is a must-see for every doctor, nurse, and
health care provider who provides medical care to adults.
Healthcare providers should follow these overarching recommendations:
- Adults 19 years of age or older with
immunocompromising conditions, functional or anatomic asplenia, CSF leaks,
or cochlear implants, and who have not previously received PCV13 or
PPSV23, should receive a dose of PCV13 first followed by a dose of PPSV23
at least 8 weeks later. Subsequent doses of PPSV23 should follow current
PPSV23 recommendations for high risk adults.
- Adults 19 years of age or older with the aforementioned
conditions (functional or anatomic asplenia, immunocompromising
conditions, or those with CSF leaks or cochlear implants) who have
previously received one or more doses of PPSV23 should be given a dose of
PCV13 one or more years after the last PPSV23 dose was received. For those
who require additional doses of PPSV23, the first such dose should be
given no sooner than 8 weeks after PCV13 and at least 5 years since the
most recent dose of PPSV23.
- Those who received one or more doses of PPSV23
before age 65 years for any indication should receive another dose of the
vaccine at age 65 years or older if at least 5 years have elapsed since
their previous PPSV23 dose. If a dose of PPSV23 was received at age 65
years or later, no additional doses of PPSV23 are recommended.
- PPSV23 recommendations remain the same for
those 65 years and older and those who are immunocompetent with chronic
medical conditions, such as diabetes or heart disease.
To learn more about pneumococcal disease and vaccines, visit the resources
listed below.
Web Sites
- Pneumococcal vaccine resources
- Recommendations,
scenarios and Q&As for health care professionals about PCV13 for
immunocompromised adults
- Table:
Medical conditions or other indications for administration of PCV13, and
indications for PPSV23 administration and revaccination for adults 19
years of age or older
ACIP
Recommendations
- Use
of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal
Polysaccharide Vaccine for Adults with Immunocompromising Conditions:
Recommendations of the Advisory Committee on Immunization Practices (ACIP)
- Updated
Recommendations for Prevention of Invasive Pneumococcal Disease Among
Adults Using the 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23)
Video
